Bacterial cytotoxins are toxic proteins produced by bacteria that damage host cells and manipulate their functions, facilitating infection.
These virulence factors disrupt innate immune cells, such as macrophages and neutrophils, impeding their ability to eliminate pathogens.
Immunoglobulin M (IgM) antibodies play a crucial role in the body's initial defense against these cytotoxins. As the first antibodies produced in a humoral immune response, IgM antibodies are essential for rapidly neutralizing pathogens and activating the complement system to clear infections.
Laboratory testing for IgM antibodies against bacterial cytotoxins is vital for diagnosing current or recent bacterial infections, particularly those involving cytotoxin-producing strains, and guiding appropriate treatment strategies.
Bacterial infections cause significant morbidity and mortality globally. Treatment typically involves broad-spectrum antibiotics, but overuse has led to multidrug-resistant strains.
PFTs, or pore-forming toxins, present in many pathogens. They contribute to virulence by damaging host cell membranes. Targeting PFTs could provide new avenues for antimicrobial prophylactics and therapeutics.
Bacterial cytotoxins are toxic proteins produced by bacteria that damage host cells and manipulate host cell functions, aiding bacterial infection.
These virulence factors target innate immune cells, such as macrophages and neutrophils, disrupting their ability to phagocytose and destroy pathogens.
By damaging the host cell's cytoplasmic membrane or enzymatically modifying key eukaryotic targets, cytotoxins can induce cell death or heavily perturb intracellular signaling pathways, leading to impaired immune responses, pathogen dissemination, host tissue damage, and disease progression.
For example, Shigella dysenteriae produces Shiga toxin, an exotoxin with cytotoxic properties capable of killing cells.
The body's immune response to Shiga toxin includes the transient production of neutralizing IgM antibodies.
Interestingly, the body does not seem to switch to production of IgG antibodies against the Shiga toxin, and IgM antibodies against the Shiga toxin disappear between 9-18 months post-infection. [4.]
Bacterial cytotoxins can be single proteins or complexes with distinct AB structure-function properties.
The A domain is responsible for catalytic activities, while the B domain includes a receptor-binding domain that determines the toxin's target cell specificity and a translocation domain that facilitates the delivery of the A domain across cellular membranes.
Pore-forming toxins (PFTs) are a subset of bacterial cytotoxins that are essential virulence factors for many pathogenic bacteria, including Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli. [5.]
PFTs disrupt host cell membranes by binding to specific receptors, forming multimers, and creating pores. This process can lead to cell lysis, release of nutrients, or escape from phagosomes.
PFTs play significant roles in infection by aiding bacterial invasion, evading immune responses, and disrupting epithelial barriers, facilitating bacterial growth and dissemination.
PFTs are secreted as water-soluble molecules that bind to specific receptors on target membranes, form multimers, and create pores in the membrane.
This process can lead to cell lysis, release of nutrients, or escape from phagosomes.
PFTs can be classified by their structure (α-helices or β-barrels) and the size of the pores they form, with different host defenses activated against small and large pores.
PFTs contribute to infection by:
The immune response against bacterial cytotoxins involves a complex interplay of cellular defense mechanisms aimed at mitigating the damage caused by these toxins.
PFTs are virulence factors employed by many pathogenic bacteria including Streptococcus pneumoniae, Staphylococcus aureus, Shigella dysenteriae, and Escherichia coli to disrupt host cell membranes and promote infection.
Common host defenses include:
PFTs can induce a robust cytokine response, with TNF-α, IL-1β, and IL-6 being particularly important in orchestrating the inflammatory response and recruiting immune cells to the site of infection.
The presence of cytotoxins and their effects on host cells can stimulate the adaptive immune response, leading to the production of memory T and B cells specific to the bacterial antigens and cytotoxins. Antibodies against bacterial cytotoxins, including IgA, IgG, and IgM antibodies are made.
Immunoglobulin M (IgM) antibodies are the first antibodies produced in a humoral immune response. They are essential in the initial defense against infections, including in the humoral response to bacterial cytotoxins.
IgM is produced early in the immune response, before B cells undergo somatic hypermutation, making them the first line of defense against pathogens.
Due to their large size, IgM antibodies are primarily found in the blood and lymphatic system. This distribution allows them to effectively target and neutralize pathogens that enter these areas.
IgM is particularly effective at activating the complement system, a critical part of the immune response that helps to clear pathogens. Its pentameric structure allows it to efficiently bind and activate complement proteins.
IgM can neutralize pathogens directly by binding to them, preventing their interaction with host cells and subsequent infection.
The quick production and high avidity of IgM antibodies are crucial for controlling infections in the bloodstream, which can have severe consequences if not managed promptly.
IgM provides an essential initial defense mechanism while other isotypes, such as IgG, are being produced and selected for higher affinity.
Laboratory testing for the presence of IgM antibodies against bacterial cytotoxins is done in blood. This test requires a blood sample via venipuncture.
Special preparation is generally not required, although it is essential to consult with the ordering provider prior to sample collection.
Testing for the presence of antibodies is generally done via Enzyme-Linked Immunosorbent Assay (ELISA) is a widely used method for detecting and quantifying Bacterial Cytotoxins IgM.
This technique utilizes specific antibodies to capture and detect IgM antibodies against bacterial cytotoxins in patient samples. ELISA offers high sensitivity and specificity, making it a reliable choice for clinical laboratories.
Optimal levels of Bacterial Cytotoxins IgM are defined by one company as: [7.]
0.2-1.6 ELISA index
Elevated Bacterial Cytotoxins IgM indicate a current or recent infection with specific strains of bacteria that produce cytotoxins.
These results should be interpreted within the context of an individual’s symptom picture, and symptoms of active infection along with elevated antibodies should prompt the appropriate treatment.
A test for Bacterial Cytotoxins antibodies should be considered in individuals with symptoms that may indicate small intestinal bowel overgrowth (SIBO), dysbiosis, or leaky gut. [6.]
Symptoms may include gas, bloating, loose stool and/or constipation, diarrhea, changes in appetite, and others.
Symptoms of acute gastrointestinal infection may also warrant this testing and can include diarrhea, nausea, vomiting, and fever.
Click here to learn more and order Bacterial Cytotoxin testing.
[1.] do Vale A, Cabanes D, Sousa S. Bacterial Toxins as Pathogen Weapons Against Phagocytes. Frontiers in Microbiology. 2016;7. doi:https://doi.org/10.3389/fmicb.2016.00042
[2.] Henkel, J.S., Baldwin, M.R., Barbieri, J.T. (2010). Toxins from bacteria. In: Luch, A. (eds) Molecular, Clinical and Environmental Toxicology. Experientia Supplementum, vol 100. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8338-1_1
[3.] Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001. The distribution and functions of immunoglobulin isotypes. Available from: https://www.ncbi.nlm.nih.gov/books/NBK27162/
[4.] Keusch GT, Jacewicz M, Levine MM, Hornick RB, Kochwa S. Pathogenesis of shigella diarrhea. Serum anticytotoxin antibody response produced by toxigenic and nontoxigenic Shigella dysenteriae 1. Journal of Clinical Investigation. 1976;57(1):194-202. doi:https://doi.org/10.1172/jci108259
[5.] Los FCO, Randis TM, Aroian RV, Ratner AJ. 2013. Role of Pore-Forming Toxins in Bacterial Infectious Diseases. Microbiol Mol Biol Rev 77:.
https://doi.org/10.1128/mmbr.00052-12
[6.] Rupa Health. Array 22 by Cyrex Laboratories. Rupa Health. Accessed August 2, 2024. https://www.rupahealth.com/lab-tests/cyrex-array-22
[7.] Rupa Health. Array 22 Sample Report.pdf. Google Docs. Accessed August 2, 2024. https://drive.google.com/file/d/1iNACwc7fXKBHgO8xZYyfD2aHpBHPPB85/view
[8.] Woida PJ, Satchell KJF. Bacterial Toxin and Effector Regulation of Intestinal Immune Signaling. Front Cell Dev Biol. 2022 Feb 16;10:837691. doi: 10.3389/fcell.2022.837691. PMID: 35252199; PMCID: PMC8888934.